Lexeo Therapeutics, Inc. (LXEO): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$268.0K

Year ended 2025-12-31

$293.0K

Trailing 12 months to 2026-06-30

+30.7%

3-year compound annual growth

2022-12-31 Depreciation & Amortization (USD) 2025-12-31

Period ended	Depreciation & Amortization	Change YoY	Source filing
2025-12-31	$268.0K	-11.8%	2026-03-30, From 2025-01-01
2024-12-31	$304.0K	+12.2%	2026-03-30, From 2024-01-01
2023-12-31	$271.0K	+125.8%	2025-03-24, From 2023-01-01
2022-12-31	$120.0K	n/a	2024-03-11, From 2022-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Depreciation & Amortization	Change YoY
Lexeo Therapeutics, Inc. (LXEO)	2025-12-31	$268.0K	-11.8%
Tectonic Therapeutic, Inc. (TECX)	2025-12-31	$1.38M	-16.4%
Coherus Oncology, Inc. (CHRS)	2025-12-31	$3.92M	-25.6%
X4 Pharmaceuticals, Inc (XFOR)	2025-12-31	$1.28M	+60.4%
Alector, Inc. (ALEC)	2025-12-31	$5.72M	+5.8%
Kyverna Therapeutics, Inc. (KYTX)	2025-12-31	$1.80M	-15.7%
MeiraGTx Holdings plc (MGTX)	2025-12-31	$12.54M	-2.2%
LENZ Therapeutics, Inc. (LENZ)	2025-12-31	$287.0K	+394.8%
DBV Technologies S.A. (DBVT)	2025-12-31	$2.99M	+9.8%

Compare LXEO, TECX, CHRS, XFOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗